Cytori Cell Research Institute, Inc. (3750.T)
JPY 679.0
(0.89%)
JPY 679.0
(0.89%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 5.81 Billion JPY | -58.72% |
| 2022 | 14.09 Billion JPY | -11.96% |
| 2021 | 16 Billion JPY | 7.26% |
| 2020 | 14.92 Billion JPY | -3.6% |
| 2019 | 15.48 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 5.36 Billion JPY | -7.76% |
| 2023 Q3 | 13.73 Billion JPY | 1.03% |
| 2023 FY | 5.81 Billion JPY | -58.72% |
| 2023 Q4 | 5.81 Billion JPY | -57.67% |
| 2023 Q2 | 13.59 Billion JPY | -1.85% |
| 2023 Q1 | 13.85 Billion JPY | -1.68% |
| 2022 Q3 | 14.07 Billion JPY | -1.14% |
| 2022 Q2 | 14.23 Billion JPY | 0.0% |
| 2022 Q4 | 14.09 Billion JPY | 0.1% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 11.731% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -380.123% |
| GNI Group Ltd. | 62.39 Billion JPY | 90.678% |
| Linical Co., Ltd. | 18.53 Billion JPY | 68.628% |
| Trans Genic Inc. | 9.81 Billion JPY | 40.716% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | -3.234% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 16.265% |
| AnGes, Inc. | 28.89 Billion JPY | 79.869% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -570.645% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 96.3% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -259.348% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | -14.692% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | -33.712% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -139.074% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -145.066% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 16.074% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -232.086% |
| Kidswell Bio Corporation | 5.08 Billion JPY | -14.37% |
| PeptiDream Inc. | 67.12 Billion JPY | 91.335% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -185.031% |
| Ribomic Inc. | 3.54 Billion JPY | -63.967% |
| SanBio Company Limited | 5.04 Billion JPY | -15.237% |
| Healios K.K. | 15.15 Billion JPY | 61.621% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -372.774% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -92.849% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -294.554% |
| StemRIM | 9.08 Billion JPY | 35.943% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 15.457% |
| FunPep Company Limited | 2.49 Billion JPY | -133.481% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -122.111% |
| Stella Pharma Corporation | 3.82 Billion JPY | -52.235% |
| TMS Co., Ltd. | 3.55 Billion JPY | -63.621% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | -0.647% |
| Cuorips Inc. | 6.18 Billion JPY | 5.957% |
| K Pharma,Inc. | 3.31 Billion JPY | -75.513% |
| Takara Bio Inc. | 123.2 Billion JPY | 95.279% |
| ReproCELL Incorporated | 9.05 Billion JPY | 35.75% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -114.204% |
| StemCell Institute Inc. | 6.54 Billion JPY | 11.107% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 16.776% |
| CellSeed Inc. | 2.46 Billion JPY | -135.883% |